Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Abstract Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanerc...

Full description

Bibliographic Details
Published in:	Arthritis Research & Therapy
Main Authors:	Josef S. Smolen, Annette Szumski, Andrew S. Koenig, Thomas V. Jones, Lisa Marshall
Format:	Article
Language:	English
Published:	BMC 2018-01-01
Subjects:	Rheumatoid arthritis Treatment Remission Low disease activity Etanercept Methotrexate
Online Access:	http://link.springer.com/article/10.1186/s13075-017-1484-9

Similar Items

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
by: Yoshiya Tanaka, et al.
Published: (2019-07-01)

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
by: Marina G. Birck, et al.
Published: (2025-07-01)

Effectiveness of Combination of Leflunomide and Methotrexate compared to Etanercept in the Treatment of Rheumatoid Arthritis: A systematic review and meta-analysis
by: Rashin Iman, et al.
Published: (2021-07-01)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
by: Chen HH, et al.
Published: (2016-02-01)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
by: Favalli EG, et al.
Published: (2018-05-01)

Evaluation of Efficacy and Safety of Etanercept and Etanercept + Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations
by: T. M. Bzarova, et al.
Published: (2016-01-01)

Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
by: Eugen Feist, et al.
Published: (2022-02-01)

Efficacy and safety of the biosimilar etanercept in the treatment of patients with rheumatoid arthritis and spondyloarthritis
by: B. G. Issayeva, et al.
Published: (2024-10-01)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
by: Tiina Levälampi, et al.
Published: (2023-03-01)

ETANERCEPT TREATMENT RESULTS IN CHILDREN WITH NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REMISSION, RECRUDESCENCE, AND ADVERSE EVENTS. RETROSPECTIVE COHORT STUDY
by: Mikhail M. Kostik, et al.
Published: (2018-05-01)

Etanercept in the treatment of Graves’ ophthalmopathy with primary hypothyroidism and rheumatoid arthritis
by: Olivera Boskovic, et al.
Published: (2020-01-01)

Predictors of Response to (Etanercept) in the Treatment of Iraqi Patients with Active Rheumatoid Arthritis
by: Nizar A. Jassim
Published: (2015-04-01)

CLINICAL EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS
by: O. A. Rumyantseva, et al.
Published: (2018-05-01)

Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
by: Majed Khraishi, et al.
Published: (2019-09-01)

Etanercept
by: Sibel Alper
Published: (2022-04-01)

Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
by: Maria N. Chamurlieva, et al.
Published: (2021-10-01)

Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders
by: S Oertle, et al.
Published: (2002-07-01)

LONG TERM FOLLOW-UP ON EFFECTIVENESS AND SAFETY OF ETANERCEPT IN JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS
by: A. A. Baranov, et al.
Published: (2015-04-01)

Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report
by: Woo Keun Song, et al.
Published: (2018-06-01)

Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits
by: Naceur Rekaya, et al.
Published: (2020-06-01)

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
by: Hisashi Yamanaka, et al.
Published: (2019-12-01)

Etanercept In the treatment of AA-amyloidosis in juvenile rheumatoid arthritis
by: H Mihels
Published: (2004-08-01)

EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
by: Anna Olegovna Pchelintseva, et al.
Published: (2014-02-01)

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology
by: Xavier M Teitsma, et al.
Published: (2018-10-01)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
by: Tanja Alexandra Stamm, et al.
Published: (2018-08-01)

Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis
by: Anna Lyakhovitsky, MD, et al.
Published: (2020-08-01)

Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis
by: Aurélio Matos Andrade, et al.
Published: (2024-11-01)

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
by: Areej S. Albahdal, et al.
Published: (2024-02-01)

RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE
by: E. L. Nasonov, et al.
Published: (2018-07-01)

Association between genetic polymorphism in tumor necrosis factor-alpha gene and adverse effects of etanercept in rheumatoid arthritis patients
by: Samer Imad Mohammed, et al.
Published: (2023-09-01)

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy
by: Abdulaziz Boqaeid, et al.
Published: (2024-06-01)

Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
by: Siegfried Wassenberg, et al.
Published: (2022-10-01)

Metabolic aspects of clinical remission prediction from baseline blood gene expression in patients with rheumatoid arthritis treated with methotrexate
by: E. V. Chetina, et al.
Published: (2019-05-01)

Not only anti-inflammation, etanercept abrogates collagen-induced arthritis by inhibiting dendritic cell migration and maturation
by: Xuechan Huang, et al.
Published: (2019-09-01)

The role of etanercept in the treatment of patients with severe rheumatoid arthritis
by: N. V. Chichasova
Published: (2013-12-01)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
by: Noriko Kimura, et al.
Published: (2019-03-01)

Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE
by: Eugen Feist, et al.
Published: (2024-02-01)

How should a patient with rheumatoid arthritis behave after achievement of remission?
by: D. E. Karateev
Published: (2016-03-01)

Effect of Monotherapy with Methotrexate, Etanercept and their Combination on the Quality of Life in Children with Early and Late Juvenile Idiopathic Arthritis: A Prospective Study
by: Anna N. Fetisova, et al.
Published: (2018-10-01)

Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study
by: Rudy Hidayat, et al.
Published: (2024-09-01)